TABLE 10

Recently identified potential therapeutic application of TP antagonists

AntagonistRouteDoseSpeciesExperimental ModelIndicationReference
GR-32191 (vapiprost)Oral (drinking water)1 mg · kg−1 · day−1MouseSTZ diabetesDiabetic retinopathyWright et al., 2009
KP-496Intratracheal30 and 100 μm/animalRatSephadex induced airway inflammationAsthmaIshimura et al., 2009
KP-496Intranasal0.003–0.05%Guinea pigOvalbumin, Japanese cedar pollen allergyAllergic rhinitisMizutani et al., 2008
ONO-3708Intradermal0.1 and 1 nmol/siteMouseTxA2-induced scratchingPruritusAndoh et al., 2007
S18886 (terutroban)Oral10 and 30 mg/kgRatUninephrectomized obese Zucker ratsType 2 diabetesSebeková et al., 2007
  • STZ, streptozotocin; ONO-3708, (1S-(1α,2β(Z),3α(S*),5α))-7-(3-((cyclopentylhydroxyacetyl)amino)-6,6-dimethylbicyclo(3.1.1)hept-2-yl)-5-heptenoic acid.